Jane Street Group LLC lifted its position in Inari Medical, Inc. (NASDAQ:NARI – Free Report) by 32.4% in the 3rd quarter, according to the company in its most recent filing with the SEC.

https://www.tipranks.com/news/the-fly/biontech-to-pay-791-5m-in-settlement-agreement-with-the-nih Truist analyst Richard Newitter raised the firm’s price target on ...

Truist analyst Richard Newitter raised the firm’s price target on Inari Medical (NARI) to $63 from $50 and keeps a Hold rating on the shares as part of a broader research note previewing 2025 in ...

Merit Medical President Joseph Wright will resign effective Jan. 3, following unspecified allegations about his conduct, the company said Monday. Chairman, CEO and founder Fred Lampropoulos was ...

Analyst Price Forecast Suggests 16.57% Upside As of December 3, 2024, the average one-year price target for Inari Medical is $66.15/share. The forecasts range from a low of $50.50 to a high of $90.30.

Analysts' ratings for Inari Medical (NASDAQ:NARI) over the last quarter vary from bullish to bearish, as provided by 6 analysts. The following table encapsulates their recent ratings, offering a ...

Oppenheimer initiated coverage of Inari Medical (NARI) with an Outperform rating and $75 price target Inari is a leader in the thrombectomy for the treatment of deep vein thrombosis and pulmonary ...

When deputies arrived, they learned that a vehicle carrying medical supplies was being delivered to a hospital in Macon. According to officials, the supplies are Technetinium 99M, a radioactive ...